Literature DB >> 15185000

Positive status of alpha-fetoprotein and des-gamma-carboxy prothrombin: important prognostic factor for recurrent hepatocellular carcinoma.

Masaki Kaibori1, Yoichi Matsui, Hidesuke Yanagida, Norio Yokoigawa, A-Hon Kwon, Yasuo Kamiyama.   

Abstract

The aim of this study was to evaluate prognostic factors after the recurrence of hepatocellular carcinoma (HCC) in patients who had undergone hepatic resection. We used univariate and multivariate retrospective analyses of 29 clinicopathologic factors in 143 patients with recurrent HCC. Patients were classified into four groups according to the positivity of tumor markers at the time of recurrence. Survival rates and prognostic factors were then compared among the four groups. Multivariate analysis revealed four independent prognostic factors at recurrence: albumin level < 3.5 g/dl ( p = 0.0003), period until recurrence </= 1 year ( p = 0.0004), positive status of alpha-fetoprotein and des-gamma-carboxy prothrombin (AFP+/DCP+) ( p < 0.0001), and portal vein invasion ( p < 0.0001). Among groups with varying status of AFP/DCP, the survival rate in patients with AFP+/DCP+ at recurrence was significantly lower than those in the other three groups (+/+ 15.9% vs. +/- 47.2%, -/+ 44.8%, or -/- 61.1% at 3 years: p < 0.05). The AFP+/DCP+ group also had significantly higher rates of the recurrence appearing </= 1 year after operation (+/+ 68.3% vs. +/- 45.2%, -/+ 41.9%, or -/- 32.5%: p = 0.0108), extrahepatic recurrence (29.3% vs. 6.5%, 9.7%, or 5.0%: p = 0.0026), and no treatment at recurrence (29.3% vs. 9.7%, 9.7%, or 5.0%: p = 0.0115). These results indicate that the tumor markers AFP and DCP are significant prognostic factors for recurrent HCC, and their monitoring is essential for improving the prognosis after recurrence.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15185000     DOI: 10.1007/s00268-004-7205-y

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  24 in total

1.  Risk factors for recurring hepatocellular carcinoma differ according to infected hepatitis virus-an analysis of 236 consecutive patients with a single lesion.

Authors:  Y Koike; Y Shiratori; S Sato; S Obi; T Teratani; M Imamura; K Hamamura; Y Imai; H Yoshida; S Shiina; M Omata
Journal:  Hepatology       Date:  2000-12       Impact factor: 17.425

2.  Which patients with hepatitis C develop liver complications?

Authors:  M H Khan; G C Farrell; K Byth; R Lin; M Weltman; J George; D Samarasinghe; J Kench; S Kaba; E Crewe; C Liddle
Journal:  Hepatology       Date:  2000-02       Impact factor: 17.425

3.  Usefulness of simultaneous determination of alpha-fetoprotein and des-gamma-carboxy prothrombin in hepatocellular carcinoma.

Authors:  A Nakao; K Taniguchi; S Inoue; A Harada; T Nonami; K Watanabe; H Takagi
Journal:  Semin Surg Oncol       Date:  1996 May-Jun

4.  Significance of resection margin in hepatectomy for hepatocellular carcinoma: A critical reappraisal.

Authors:  R T Poon; S T Fan; I O Ng; J Wong
Journal:  Ann Surg       Date:  2000-04       Impact factor: 12.969

5.  Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients.

Authors:  Y Koike; Y Shiratori; S Sato; S Obi; T Teratani; M Imamura; H Yoshida; S Shiina; M Omata
Journal:  Cancer       Date:  2001-02-01       Impact factor: 6.860

6.  Production of embryonal serum alpha-globulin by hepatomas: review of experimental and clinical data.

Authors:  G I Abelev
Journal:  Cancer Res       Date:  1968-07       Impact factor: 12.701

7.  Risk factors for recurrence after resection of hepatitis C virus-related hepatocellular carcinoma.

Authors:  S Kubo; K Hirohashi; H Tanaka; T Tsukamoto; T Shuto; T Ikebe; T Yamamoto; K Wakasa; S Nishiguchi; T Kuroki; H Kinoshita
Journal:  World J Surg       Date:  2000-12       Impact factor: 3.352

8.  Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death.

Authors:  F Degos; C Christidis; N Ganne-Carrie; J P Farmachidi; C Degott; C Guettier; J C Trinchet; M Beaugrand; S Chevret
Journal:  Gut       Date:  2000-07       Impact factor: 23.059

9.  Risk factors for intrahepatic recurrence of hepatocellular carcinoma in cirrhotic patients treated by percutaneous ethanol injection.

Authors:  M Pompili; G L Rapaccini; F de Luca; E Caturelli; A Astone; D A Siena; M R Villani; A Grattagliano; A Cedrone; G Gasbarrini
Journal:  Cancer       Date:  1997-04-15       Impact factor: 6.860

10.  Clinical significance of simultaneous determinations of alpha-fetoprotein and des-gamma-carboxy prothrombin in monitoring recurrence in patients with hepatocellular carcinoma.

Authors:  Y Aoyagi; M Oguro; M Yanagi; Y Mita; T Suda; Y Suzuki; K Hata; K Ichii; H Asakura
Journal:  Cancer       Date:  1996-05-01       Impact factor: 6.860

View more
  8 in total

1.  Cutaneous and colonic metastases after resection of hepatocellular carcinoma.

Authors:  Masaki Kaibori; Mika Morita; Shuuji Tagami; Yoichiro Uchida; Hironori Tanaka; Kazuhiko Yoshioka; Yu Takahashi; Noriko Sakaida; Yoshiko Uemura; Toshihito Seki; Kazuichi Okazaki; Yasuo Kamiyama
Journal:  Dig Dis Sci       Date:  2007-03-07       Impact factor: 3.199

2.  The tumor marker score is an independent predictor of survival in patients with recurrent hepatocellular carcinoma.

Authors:  Yukiyasu Okamura; Ryo Ashida; Takaaki Ito; Teiichi Sugiura; Keita Mori; Katsuhiko Uesaka
Journal:  Surg Today       Date:  2014-12-20       Impact factor: 2.549

3.  A nomogram for predicting the risk of postoperative recurrence of hepatitis B virus-related hepatocellular carcinoma in patients with high preoperative serum glutamyl transpeptidase.

Authors:  Jia-Si Zhang; Zhi-Heng Wang; Xing-Gang Guo; Ji Zhang; Jun-Sheng Ni
Journal:  J Gastrointest Oncol       Date:  2022-02

4.  Significance of a preoperative tumor marker gradient for predicting microvascular invasion in cases of hepatocellular carcinoma.

Authors:  Satoshi Koizumi; Shingo Yamashita; Satoshi Matsumura; Kazuhisa Takeda; Takuya Minagawa; Shinjiro Kobayashi; Taizo Hibi; Masahiro Shinoda; Itaru Endo; Minoru Tanabe; Masakazu Yamamoto; Takehito Otsubo
Journal:  Mol Clin Oncol       Date:  2020-01-10

Review 5.  Biomarkers for the early diagnosis of hepatocellular carcinoma.

Authors:  Nobuhiro Tsuchiya; Yu Sawada; Itaru Endo; Keigo Saito; Yasushi Uemura; Tetsuya Nakatsura
Journal:  World J Gastroenterol       Date:  2015-10-07       Impact factor: 5.742

6.  Des-gamma-carboxy prothrombin as an important prognostic indicator in patients with small hepatocellular carcinoma.

Authors:  Kenichi Hakamada; Norihisa Kimura; Takuya Miura; Hajime Morohashi; Keinosuke Ishido; Masaki Nara; Yoshikazu Toyoki; Shunji Narumi; Mutsuo Sasaki
Journal:  World J Gastroenterol       Date:  2008-03-07       Impact factor: 5.742

7.  Impact of PIVKA-II in diagnosis of hepatocellular carcinoma.

Authors:  Nadia I Zakhary; Sherif M Khodeer; Hanan E Shafik; Camelia A Abdel Malak
Journal:  J Adv Res       Date:  2013-01-11       Impact factor: 10.479

8.  Diagnostic Evaluation of Des-Gamma-Carboxy Prothrombin versus α-Fetoprotein for Hepatitis B Virus-Related Hepatocellular Carcinoma in China: A Large-Scale, Multicentre Study.

Authors:  Jun Ji; Hao Wang; Yan Li; Lei Zheng; Yuepeng Yin; Zhenzhen Zou; Feiguo Zhou; Weiping Zhou; Feng Shen; Chunfang Gao
Journal:  PLoS One       Date:  2016-04-12       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.